You just read:

Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis

News provided by

Regeneron Pharmaceuticals, Inc.

Aug 06, 2019, 01:04 ET